Aim: To explain the missing heritability after the genome-wide association studies era, sequencing studies allow the identification of low-frequency variants with a stronger effect on disease risk. Common variants in the interleukin 10 gene (IL10) have been consistently associated with Behc ßet's disease (BD) and the goal of this study is to investigate the role of low-frequency IL10 variants in BD susceptibility.
INTRODUCTION
Behc ßet's disease (BD) is an immune-mediated inflammatory vasculitis with a large clinical spectrum, including oral aphthae, genital ulcerations, uveitis, as well as vascular, neurological, articular, pulmonary and gastrointestinal manifestations. 1 In complex diseases such as BD, genome-wide association studies (GWAS) have provided new insights into disease physiopathology through the identification of common genetic variants (minor allele frequencies [MAF] greater than 5%) associated with disease susceptibility. 2, 3 However, these single nucleotide polymorphisms (SNPs) typically confer a small disease risk and only explain a modest portion of the overall genetic variance. 4 In addition, many SNPs captured by GWAS seem to be in linkage disequilibrium with the causal variant rather than to be causal themselves, and most of the associated genetic variants do not have any known or obvious functions. 5, 6 Moreover, low-frequency (1% ≤ MAF < 5%) and rare variants (MAF < 1%) are not sufficiently frequent to be captured by GWAS and current efforts to discover these variants by sequencing have focused on genes within regions implicated by GWAS. 7 In addition to the well-established human leukoctye antigen (HLA) locus, common polymorphisms in interleukin (IL23R-IL12RB2) and IL10 have been recently associated with BD in two independent GWAS in Turkish and Japanese datasets 2, 3 and replicated in an Iranian sample 8 and in a recent meta-analysis. 9 IL10 has a central role in the suppression of inflammatory cytokines inhibiting the costimulatory activity of macrophages for T-cell and natural killer (NK)-cell activation. IL10 deficiencies add to the group of primary immunodeficiencies and result in severe deregulation of the immune system. 10 Interestingly, elevated IL10 levels have been observed in the sera and mucocutaneous lesions of BD patients. 11 It is likely that relative levels of cytokine production may be important in the determination of disease onset, progression and outcome, and therefore we hereby chose to focus our attention on IL10.
To further investigate the role of low-frequency IL10 variants in BD susceptibility, we sequenced the complete IL10 gene and neighboring genomic regions, including two well-conserved regions in the putative promoter. The existence and association with BD of identified novel variants was then assessed in a second independent dataset.
PATIENTS AND METHODS

Study subjects
The 76 Portuguese BD patients were recruited throughout Portugal and 104 Portuguese controls were selected among blood bank donors or healthy volunteers using the same evaluation procedures used for the cases; individuals were included as controls when negative for BD, any other rheumatologic or autoimmune disorder, oral and genital aphthosis. The Iranian dataset included 1787 unrelated subjects (964 BD cases and 823 controls) recruited at the Rheumatology Research Center of Shariati Hospital (Tehran University of Medical Sciences, Tehran, Iran). The diagnosis of BD was made according to the revised International Criteria for Behc ßet's Disease. 1 Patients with age at onset of BD after 60 years were excluded. The clinical and demographic features of the participants were obtained by medical interview at the time of blood sampling and inspection of medical records. All participants were informed of the study, provided informed written consent and the study was conducted according to the Declaration of Helsinki. This study received ethics approval from the ethics committees in Portugal (Hospital Infante D. Pedro and Instituto Portugueŝ de Reumatologia) and Iran (Tehran University for Medical Sciences).
Sample preparation
Blood samples were drawn into ethylenediaminetetraacetic acid (EDTA) tubes and stored at À20°C until genomic DNA was extracted using QIAamp â DNA Blood Maxi kits (Qiagen, Germantown, MD, USA) or a salting out procedure and diluted in Tris-EDTA (TE) buffer. The concentrations of extracted DNA were determined by Nanodrop using absorbance readings at 260 nm and the DNAs were then stored at 4°C.
Sequencing
To sequence the IL10 open reading frame and two conserved promoter regions, 13 primer sets (Table S1) A 10 lL sequencing reaction was prepared with 90 ng of PCR product, 1 9 reaction buffer, 1 9 BigDye v3.1 Cycle Sequencing Kit (Applied Biosystems) and 0.32 pmol/lL of primer (forward or reverse). The sequencing reaction was then subjected to thermal cycling (96°C for 1 min, followed by 25 cycles of (96°C for 10 sec, 50°C for 5 sec, 60°C for 110 sec), followed by a rapid thermal ramp to 4°C) and run on an automated sequencer (ABI 3730XL, Applied Biosystems) in the DNA Sequencing Service from the Genomics Unit at the Instituto Gulbenkian de Ciência in Portugal. 
Genotyping
Five variants were genotyped using a Sequenom iPlex assay (Sequenom, San Diego, CA, USA) according to the manufacturer's protocol, with detection in a Sequenom MassArray K2 platform. The primer sequences (Table S2) were designed using Sequenom MassARRAY Assay Design software version 3.0 and the genotyping assay was performed using the Genotyping Service from the Genomics Unit at the Instituto Gulbenkian de Ciên-cia, Portugal. Extensive quality control was performed with the use of eight HapMap controls of diverse ethnic affiliation, along with sample duplication within and across plates, a Mendelian inheritance check in three large pedigrees, and a call rate for each SNP > 90%. Genotype determinations were performed with the investigators blinded to the affection status (i.e., case or control). Individual DNA samples with genotyping success rate across all SNPs < 85% were also excluded.
Transcription factor binding sites
The Integrated Regulation from ENCODE (Transcription Factor ChIP-seq from ENCODE) and the ENCODE Transcription Factor Binding (Transcription Factor ChIP-seq Uniform Peaks from ENCODE/Analysis, ENCODE March 2012 Freeze) tracks on the UCSC genome browser (http://genome.ucsc.edu/) were used to determine if the identified novel variants are located in putative transcription factor binding sites.
RESULTS
IL10 variant discovery
To identify novel low-frequency variants in IL10 associated with BD, we first sequenced a 7.7 kb genomic region encompassing the complete IL10 gene plus 0. 9 In these 50 BD patients, we did not detect rare IL10 coding variants, but we identified 28 known SNPs with MAF ranging from 0.010 to 0.390, and five previously undescribed single nucleotide variants (SNVs) in a heterozygous state in five BD patients ( Table 2 ). The novel variants are located in the IL10 3 0 untranslated region (ss836185595), in intron 3 (ss836185596 and ss836185602), and in the putative IL10 promoter region (ss836185598 and ss836185604).
Association of novel SNVs with BD
To assess if these five novel low-frequency IL10 variants are specific to BD patients and/or to the Portuguese population, we genotyped them in an additional Portuguese sample (26 cases and 104 controls) and in an Iranian dataset (964 cases and 823 controls) with the demographic and clinical characteristics shown in Table 1 . ss836185595 was detected in one Iranian control individual (Table 2 ) and therefore constitutes a new rare variant found in different populations and not specific to BD patients. The remaining four SNVs (ss836185596, ss836185602, ss836185598 and ss836185604) were not found in this second Portuguese dataset or in the Iranian cases and controls (Table 2) . ENCODE data annotated on the UCSC genome browser showed that the reference sequences of these four novel SNVs lie in transcription factor binding sites (ss836185596: Pol2; ss836185602: NFKB, STAT3, TBP, Oct-2, POU2F2, Pol2, and Pol2-4H8; ss836185598: Pol2, NFKB, TCF12, p300, BATF, EBF1_ 
DISCUSSION
We identified four novel IL10 non-coding variants in four Portuguese BD patients which were absent in Portuguese controls and in a large dataset of Iranian BD cases and controls. Even though the approaches were different (e.g., whole gene sequencing vs. exonic sequencing), our results are consistent with those from a recent report by Kirino et al. 7 where deep exonic resequencing of IL10 (in 766 patients and 768 matched controls of Japanese or Turkish origin, distributed over 32 DNA pools) led to the identification of five non-synonymous rare mutations (G15R, M40V, R124Q, H127R, K315E). A meta-analysis of the associations (in a dataset of 528 Japanese BD cases and 586 controls and in a dataset of 1933 Turkish BD cases and 1872 controls) showed that these five rare mutations were not collectively associated with BD in any of the three burden tests assayed. 7 These authors did not screen the intronic regions of IL10 and therefore it is unclear whether there would be an over-representation of noncoding variants among their patients when compared to controls.
Since the novel low-frequency variants are not in coding regions, we cannot predict their potential functional impact using algorithms such as SIFT 12 or PolyPhen2, 13 and therefore we cannot test their association with BD using currently available tests such as the C-alpha test.
14 Our work highlights the need to develop bioinformatics and statistical tools capable of estimating the impact of non-coding variants (e.g., in splice sites, in introns or in the promoter region) and to incorporate these predictions into an association test. The approach to perform mutation discovery in BD patients only relies on the assumptions that cases carry deleterious mutations and controls do not harbor protective alleles. It is a cost-effective strategy when non-synonymous variations are not found in patients, as it avoids screening the controls. The lack of variant discovery in the controls may introduce a bias in our study as we may have missed protective variants, but this possibility is unlikely and not supported by the study by Kirino et al. The new variants we identified may play a role in gene expression regulation through modification of transcription factor binding sites or DNA methylation patterns, especially those located in the promoter region. At this stage, we lack information on the specific impact of these new variants in IL10 function to decipher whether these polymorphisms contribute or not to BD. Thus, gene expression studies and functional analyses of IL10 variants, as well as the identification of the genetic/environmental factors, are needed to reinforce the potential implication of this gene in the susceptibility to BD.
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